1. Cell Cycle/DNA Damage
    Epigenetics
  2. PARP

Nicotinamide (Synonyms: Niacinamide; Nicotinic acid amide; Vitamin B3)

Cat. No.: HY-B0150 Purity: 99.94%
Data Sheet SDS Handling Instructions

Nicotinamide is a water-soluble vitamin, an active component of coenzymes NAD and NADP, and acts as poly (ADP-ribose) polymerase (PARP) inhibitor.

For research use only. We do not sell to patients.
Nicotinamide Chemical Structure

Nicotinamide Chemical Structure

CAS No. : 98-92-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
1 g $50 In-stock
5 g $65 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Nicotinamide is a water-soluble vitamin, an active component of coenzymes NAD and NADP, and acts as poly (ADP-ribose) polymerase (PARP) inhibitor.

In Vitro

Pretreatment with the poly (ADP-ribose) polymerase (PARP) inhibitor nicotinamide is able to prevent HCN2 cell death. When nicotinamide is added prior to t-BuOOH, it is able to prevent neuronal cell death and inhibit apoptosis. Nicotinamide-pretreated neurons have higher expression levels of inhibitors of apoptosis (IAP) genes[1]. Nicotinamide inhibits vasoconstriction by ET. Nicotinamide also alleviates oxidative stress, which exacerbates PE and FGR[3].

In Vivo

Normal and streptozotocin-nicotinamide induced adult male diabetic rats receive quercetin (10, 25 and 50 mg/kg/bw) orally, and cause significant decrease in FBG and cardiac injury marker levels with increased in insulin levels[2]. Nicotinamide improves maternal hypertension, proteinuria, and glomerular endotheliosis in RUPP mice. Moreover, nicotinamide prolongs pregnancies, and improves survival and growth of the embryos in RUPP PE mice[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02140814 Alan Yu, MB, BChir|University of Kansas Medical Center Polycystic Kidney Disease May 2014 Phase 2
NCT02558595 University of Kansas Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Polycystic Kidney Disease September 2015 Phase 2
NCT00508885 Washington University School of Medicine Hyperphosphatemia October 2006 Phase 1|Phase 2
NCT00316472 Washington University School of Medicine Hyperphosphatemia April 2006 Phase 1
NCT00605930 University of Louisville Progressive Supranuclear Palsy April 2004
NCT00691210 Columbia University|Merck Sharp & Dohme Corp. Hodgkin's Disease|Non-Hodgkin's Lymphoma June 2008 Phase 1
NCT02701127 Beth Israel Deaconess Medical Center Acute Kidney Injury March 2016 Early Phase 1
NCT01542138 Universidad Autonoma de San Luis Potosí|Hospital Central Dr. Ignacio Morones Prieto Hyperpigmentation July 2011 Phase 4
NCT00033436 Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI) Bladder Cancer October 2000 Phase 3
NCT00140166 Beersheva Mental Health Center|Supported by a Hilton Family Foundation grant to|International Schizophrenia Foundation Acute Schizophrenia July 2005 Phase 4
NCT00893724 Mid-Atlantic Retina Consultations, Inc.|West Virginia University Neovascular Age-related Macular Degeneration|Diabetic Macular Edema June 2009
NCT01381354 University of Iowa|Direct MS Canada|DJO Incorporated|Pinnaclife Inc.|TZ Press, LLC Multiple Sclerosis October 2010 Phase 1
NCT02213094 University of North Carolina, Chapel Hill Pregnancy Induced Hypertension|Superimposed Preeclampsia|Hypertension October 2013 Phase 1
NCT02689882 University of Washington|National Heart, Lung, and Blood Institute (NHLBI) Metabolic Disturbance November 2015 Phase 1
NCT02416739 Il Yeong Park, Ph.D.|Chungbuk National University Non-Small-Cell Lung Carcinoma March 2015 Phase 2|Phase 3
NCT01011699 Centre Hospitalier Universitaire, Amiens Chronic Renal Failure|Hemodialysis January 2010 Phase 3
NCT03061474 University of California, Irvine Alzheimer's Disease|Mild Cognitive Impairment June 1, 2017 Phase 2
NCT03151707 Mclean Hospital Healthy July 2017 Phase 4
NCT00580931 University of California, Irvine|Alzheimer's Association Alzheimer's Disease January 2008 Phase 1|Phase 2
NCT01763424 Isfahan University of Medical Sciences Psoriasis July 2011 Phase 2|Phase 3
NCT02950441 University of Birmingham Aging June 2016 Phase 2
NCT01589809 Imperial College London Neurodegenerative Disorders June 2012 Phase 2
NCT02835664 Maastricht University Medical Center|Dutch Heart Foundation Obesity|Insulin Resistance December 2016
NCT02300740 Aarhus University Hospital|University of Copenhagen Healthy Participants December 2014 Early Phase 1
NCT01200784 Medice Arzneimittel Pütter GmbH & Co KG Chronic Kidney Disease|Hemodialysis|Hyperphosphatemia August 2010 Phase 2
NCT02258074 John Kusek|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chronic Kidney Disease March 2015 Phase 3
NCT02812238 National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) Atherosclerosis|Diabetes|Coronary Artery Disease June 10, 2016 Phase 2
NCT03136705 Northwestern University Healthy February 3, 2016 Phase 1
NCT02303483 Aarhus University Hospital|University of Copenhagen Obese January 4, 2016
NCT01619228 Children's Hospital Medical Center, Cincinnati|Procter and Gamble Premature Birth of Newborn April 2012
NCT02721537 Mayo Clinic|University of Minnesota - Clinical and Translational Science Institute|Thorne Research Inc. Concussion, Mild September 2016
NCT02942888 The University of Texas Health Science Center at San Antonio|University of Texas|South Texas Veterans Health Care System Mild Cognitive Impairment|NAD October 2016
NCT03019666 Masonic Cancer Center, University of Minnesota Multiple Myeloma|Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Indolent B Cell Lymphoma|Primary Mediastinal Lymphoma|Lymphoplasmacytic Lymphoma March 2017 Phase 1
NCT01368887 DermiPsor, Ltd. Psoriasis April 2013 Phase 2
NCT01085981 East Suburban Ob Gyn Female Sexual Dysfunction April 2010
NCT02758990 Verifomics LLC Obesity|Rhinitis|Rhinitis, Allergic|Respiratory Sounds|Dyspnea|Headache|Migraine Disorders|Arthritis|Arthralgia|Anxiety|Sleep Initiation and Maintenance Disorders|Sleep Deprivation March 2016
NCT00519714 Montreal Heart Institute|Commonwealth Medical Clinic|Institut de Recherches Cliniques de Montreal|Clinique des maladies lipidiques de Québec|Centre de médecine genique communautaire|Omnispec clinical research Inc|Manna Research|St. Jerome Medical Research Inc.|Royal Victoria Hospital, Canada|Hotel Dieu Hospital|St Michael's Hospital Health Center|Cambridge Cardiac Care Centre|Maritime Research Center|Rhodin Recherche Clinique|Queen Health Sciences Centre|First Line Medical Ltd|Diabetes Research, Vancouver General Hosp|The Allin Clinic|St Paul's Hospital Healthy Heart Clinical Trial|The Clinical Trials Centre|Recherche Invascor Inc|MSHJ Research Associates|Dr.Kim W Tan Hypertriglyceridemia September 2007 Phase 2|Phase 3
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 8.1887 mL 40.9433 mL 81.8867 mL
5 mM 1.6377 mL 8.1887 mL 16.3773 mL
10 mM 0.8189 mL 4.0943 mL 8.1887 mL
Animal Administration
[2]

Nicotinamide is dissolved in normal saline.

DM is induced via a single intraperitoneal (i.p) injection of nicotinamide (110 mg/kg/body weight) dissolved in normal saline 15 min prior to streptozotocin (STZ) (55 mg/kg/body weight) injection, which is dissolved in a freshly prepared 0.1mol/Lcitrate buffer (pH 4.5). These injections are given following an overnight fast. Control rats (n=6) are injected with the same amount of solvent. In order to prevent hypoglycemia in the first 24 h following STZ injection, rats are allowed to have free access to water with 5% dextrose (D5W). Three days after STZ-nicotinamide injection, rats with FBG levels greater than 7.0 mM are considered as diabetic. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

122.12

Formula

C₆H₆N₂O

CAS No.

98-92-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Nicotinamide
Cat. No.:
HY-B0150
Quantity: